Previous 10 | Next 10 |
Savara (SVRA): Q3 GAAP EPS of -$0.18 misses by $0.01.Revenue of $256k.Cash, cash equivalents, and short-term investments of $94.3MPress Release For further details see: Savara EPS misses by $0.01
Company Outlines Near-Term Priorities Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update. “After recently joining the management team, ...
Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Offic...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT. Interested parties can access a live audio webcast on t...
Inhaled Molgramostim Improved Outcomes that Reflect Physiological, Radiological, Biochemical, and Clinical Manifestations of aPAP Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The ...
Akebia reports data for its anemia drug candidate Akebia Therapeutics Inc. ( AKBA ) reported top-line data from the second of its two global Phase 3 cardiovascular outcomes programs, PRO2TECT. The two studies were designed to assess the efficacy and safety of vadadustat in comparison to ...
Citing a range of factors, including COVID-19 disruptions, that have compromised the expected outcome, Savara (NASDAQ: SVRA ) has discontinued the Phase 2a exploratory study, ENCORE , assessing lead drug Molgradex for the treatment of nontuberculous mycobacterial lung infection in cysti...
Study Stopped Enrolling in March 2020 Due to Limitations Caused by COVID-19 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the tre...
Savara Inc (SVRA) Q2 2020 Results Conference Call August 06, 2020 04:30 PM ET Company Participants Anne Erickson - Head Investor Relations Robert Neville - Chief Executive Officer Badrul Chowdhury - Chief Medical Officer Taneli Jouhikainen - President and Chief Business Office...
Savara (NASDAQ: SVRA ) : Q2 GAAP EPS of -$0.16 beats by $0.04 . More news on: Savara Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a ra...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fir...
Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage ...